Last update 23 Nov 2024
Apocyanin
Last update 23 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Acetovanillone, apocynin |
Target |
Mechanism NOX inhibitors(NADPH oxidase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC9H10O3 |
InChIKeyDFYRUELUNQRZTB-UHFFFAOYSA-N |
CAS Registry498-02-2 |
Related
8
Clinical Trials associated with ApocyaninA placebo-controlled, double-blinded, randomized, dose-finding trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
A placebo-controlled, double-blinded, randomized, trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection: A Clinical Trial
100 Clinical Results associated with Apocyanin
Login to view more data
100 Translational Medicine associated with Apocyanin
Login to view more data
100 Patents (Medical) associated with Apocyanin
Login to view more data
2,157
Literatures (Medical) associated with Apocyanin01 Feb 2025FOOD CHEMISTRY
Integrated targeted and untargeted metabolomics profiling of Vanilla species from the Atlantic Forest: Unveiling the bioeconomic potential of Vanilla cribbiana
Article
Author: Koblitz, Maria Gabriela Bello ; da Silva Oliveira, Joana Paula ; Garrett, Rafael ; Macedo, Andrea Furtado
In this study, we employ both targeted and untargeted approaches to explore the metabolomic profiles of Vanilla spp., with a particular focus on V. cribbiana (VCR) and its comparison with V. planifolia (VP). We also examine V. bahiana and V. chamissonis using targeted approaches. Through advanced analytical techniques, our untargeted LC-HRMS approach led to the annotation of 60 metabolites, revealing a complex chemical composition with 34 novel compounds in the Vanilla genus in VCR and VP. These findings highlight significant flavoring compounds and lay the foundation for a subsequent quantitative estimation approach. Our targeted analysis, which measured key molecules, underscores VCR's potential in producing vanillin and acetovanillone at levels comparable to the commercially valuable VP and even higher levels of vanillic acid. This research enriches our understanding of flavor composition in vanilla species and emphasizes the importance of exploring wild relatives of vanilla crop for sustainable production and biodiversity conservation.
01 Jan 2025CHEMICO-BIOLOGICAL INTERACTIONS
Activation of protein kinase B rescues against thapsigargin-elicited cardiac dysfunction through regulation of NADPH oxidase and ferroptosis
Article
Author: Wang, Xiaohu ; Li, Feng-Juan ; Lin, Ling ; Ren, Jun ; Lin, Jie ; Reiter, Russel J. ; Zhu, Shuyi ; Wang, Guizhen ; Chen, Shuying ; Reiter, Russel J ; Ashrafizadeh, Milad ; Zhang, Yingmei ; Cheng, Yong
Endoplasmic reticulum (ER) stress is a known contributor to cardiac remodeling and contractile dysfunction. Although NADPH oxidase has been implicated in ER stress-induced organ damage, its specific role in myocardial complications resulting from ER stress remains unclear. This study aimed to investigate the possible involvement of NADPH oxidase in ER stress-induced myocardial abnormalities and to evaluate the impact of Akt constitutive activation on these myocardial defects. Mice with cardiac-specific overexpression of active mutant of Akt (Myr-Akt) and their wild-type (WT) littermates were treated with ER stress instigator thapsigargin (1 mg/kg, i. p. 72 hrs) before evaluating myocardial morphology and function. Our results noted that thapsigargin significantly impaired echocardiographic parameters and cell shortening indices, including elevated LVESD, decreased ejection fraction, fractional shortening, peak shortening, electrically-stimulated intracellular Ca2+ release, and cardiomyocyte survival. These functional deteriorations were accompanied by upregulation of NADPH oxidase, O2- production, mitochondrial damage, carbonyl formation, lipid peroxidation, apoptosis, and interstitial fibrosis, with unchanged myocardial size. Constitutive Akt hyperactivation did not generate any response on myocardial morphology and function, although it greatly suppressed or nullified thapsigargin-induced myocardial remodeling and dysfunction. Thapsigargin also triggered dephosphorylation of Akt and its downstream signal GSK3β, along with development of ferroptosis, all of which were nullified by Akt hyperactivation. In vitro studies further revealed that thapsigargin provoked cardiomyocyte mechanical anomalies and lipid peroxidation, similar to in vivo results. These effects were reverted by inhibitors of NADPH oxidase and ferroptosis (apocynin and LIP1). Collectively, our data denote an important protective role for Akt hyperactivation in thapsigargin-evoked myocardial anomalies, likely through NADPH oxidase-mediated regulation of ferroptosis.
01 Dec 2024MOLECULAR AND CELLULAR ENDOCRINOLOGY
Paricalcitol prevents renal tubular injury induced by ischemia-reperfusion: Role of oxidative stress, inflammation and AT1R
Article
Author: Cirilo, Marry Aneyts de Santana ; Lima, Natália Kryzia dos Santos ; Gomes, José Anderson da Silva ; Albuquerque, Jéssica Santos Schirato ; Vieira, Leucio Duarte ; Ribeiro, Fernanda Priscila Barbosa ; Siqueira, Lucas Cristiano da Silva ; Tenorio, Fernanda das Chagas Angelo Mendes ; Lima, Natália Kryzia Dos Santos ; Santos, Valéria Bianca de Souza ; Carvalho, Jennyfer Martins de ; Silva, Jeoadã Karollyne
The vitamin D receptor (VDR) is associated with antioxidative and anti-inflammatory effects and modulation of the renin-angiotensin-aldosterone system. This study evaluated whether VDR agonist paricalcitol protects renal ischemia-reperfusion (IR) induced tubular injury in rats by evaluating: 1) ATP-dependent tubular Na+ transport; 2) renal redox signaling; 3) renal content of proinflammatory cytokines TNF-α and IL-6; and 4) renal content of renin and angiotensin II receptor type 1 (AT1R). Paricalcitol prevented IR-induced tubular injury, evidenced by the prevention of histopathological changes and renal fibrosis with preservation of the activity of ATP-dependent Na+ transporters in the renal cortex. Paricalcitol decreased renal oxidative stress by reducing NADPH oxidase activity and increasing catalase. Paricalcitol also decreased the renal content of TNF-α, IL-6, and AT1R. The NADPH oxidase inhibitor apocynin did not present additive protection to paricalcitol-induced effects. The protective effects of paricalcitol on tubular injury induced by renal IR may dependent on the modulation of redox and proinflammatory signaling and renal angiotensin II/AT1R signaling.
2
News (Medical) associated with Apocyanin16 Jan 2024
Clinical ResultPhase 2Phase 1
100 Deals associated with Apocyanin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Atherosclerosis | Phase 1 | - | - | - |
| Diabetic Neuropathies | Phase 1 | - | - | - |
| Hypertension | Phase 1 | - | - | - |
| Inflammatory Bowel Diseases | Phase 1 | - | - | - |
| Parkinson Disease | Phase 1 | - | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | pzbhygukhh(qfhkfvjhvd) = eypprbjpbc pldjspcmhj (hlvbcsufdx ) | Positive | 05 Jun 2024 | ||
xqtnkwuwnk(bmzkkxpbky) = pokuezebyp tqxaksujws (ddpnhnffjp ) View more | |||||||
Not Applicable | - | Apocynin and paeonol (APPA) | lbbqblithj(txbqfolrdz) = qaauacwtnn mjqnmexbyb (oiaxbokngp ) | Positive | 03 Jun 2020 | ||
Not Applicable | - | - | eoqxemyfvy(mnaztsfuyw) = sawwwwsjky kifymxoals (qcmlkkdogq ) View more | - | 01 Sep 2011 | ||
Not Applicable | 14 | yocsjhkfie(blhikkivxk) = riydabsrcr okfdzpzakm (tuitceswly ) View more | Positive | 01 Sep 2011 | |||
Placebo | yocsjhkfie(blhikkivxk) = wwnuvttuiy okfdzpzakm (tuitceswly ) View more | ||||||
Not Applicable | - | - | bvhjflvbrn(tjqgoocwrg) = ayyhjtbiqa jboxxppiuv (fyeujrnihf ) View more | - | 01 Sep 2011 | ||
Placebo | bvhjflvbrn(tjqgoocwrg) = jjdcjohixq jboxxppiuv (fyeujrnihf ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free